Diabetes combo trial pulled before it even started

NCT ID NCT06560333

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study planned to test whether adding two newer diabetes drugs (Forxiga and Januvia) to standard metformin treatment could better control blood sugar in people with type 2 diabetes. It aimed to enroll adults aged 18–80 whose diabetes was not well controlled on metformin alone. However, the trial was withdrawn before any participants were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Forxiga (dapagliflozin) and Januvia (sitagliptin) combined with metformin

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Eurofarma Laboratorios S.A

    São Paulo, São Paulo, 06696-00, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.